Upcoming event

Tags

Abiraterone, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, ARCHES, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BHC80, Biochemical recurrence, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, hormone-sensitive, HORRAD, HRQL, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, Prognosis, Prognostic model, Prostasomes, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PSA, PSA flare, PSA kinetics, PSA screening, PSMA PET/CT, PTEN, Quality of life, Radiation therapy, Radical prostatectomy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

The Lancet Journal, June 2019

Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer

European Urology, June 2019

Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens

BJU Int., July 2019

Risk of metastatic disease on 68Ga‐PSMA PET/CT scan for primary staging of 1253 men at the diagnosis of prostate cancer

BJU International, May 2019

Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the international multicentre retrospective CATS database

European Urology Oncology, Volume 1, Issue 6, December 2018, Pages 467-475

Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients

June 2019

Patient-reported quality of life following stereotactic body radiotherapy and conventionally fractionated external beam radiotherapy compared with active surveillance among men with localized prostate cancer

European Urology, February 2019

Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475)

May 2019

Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC)

May 2019

Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer

European Urology Oncology, Volume 1, Issue 1, May 2018, Pages 78-82

Establishment of novel intraoperative monitoring and mapping method for the cavernous nerve during robot-assisted radical prostatectomy: Results of the phase I/II, first-in-human, feasibility Study

European Urology 2019 May 15

RNA splicing of the BHC80 gene contributes to neuroendocrine prostate cancer progression

European Urology, March 2019

PreviousNext